Maya Ben Lassan1, Yael Laitman2, Lital Keinan-Boker1,3, Barbara Silverman1,4, Eitan Friedman5,6. 1. Israeli National Cancer Registry, Ministry of Health, Tel-Hashomer, Ramat Gan, Israel. 2. The Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, 52621, Ramat Gan, Israel. 3. School of Public Health, University of Haifa, Haifa, Israel. 4. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. The Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, 52621, Ramat Gan, Israel. eitan.friedman@sheba.gov.il. 6. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. eitan.friedman@sheba.gov.il.
Abstract
BACKGROUND: There are limited data on whether primary diagnosis of meningioma may be associated with development of secondary primary cancer (SPC). METHODS: All meningioma cases (ICD-O-3 morphology codes 9530/0-9539/3) diagnosed in Jewish Israelis ≥ 20 years 1990 through 2015 registered in the Israel National Cancer Registry (INCR) were retrieved. All subsequent cancers occurring more than 6 months after meningioma diagnosis were identified. Risk of secondary cancer (SPC) was compared to cancer risk in the general population through the calculation of standardized incidence ratios (SIRs) and excess absolute risks (EARs). SIRs were stratified by type of second cancer, sex, and age group. Cox regression models were used to estimate hazard ratios of developing SPC. RESULTS: Overall, 8044 meningioma cases were identified: mean age at diagnosis was 64.0 ± 14.1 years. Of these, 927 (11.5%) were diagnosed with SPC (SIR 1.6, 95% CI 1.5-1.7). SPC risk was elevated in men (SIR 1.6, 95% CI 1.5-1.9) and women (SIR 1.6, 95% CI 1.5-1.8) diagnosed with meningioma in univariable analyses. Cancers most commonly encountered in the studied population were breast (17.6%), colorectal (13.4%), lung (8.1%), prostate (5%), and bladder (4.6%) cancer. In multivariable analyses, 10+ year increment in age at meningioma diagnosis was significantly associated with higher risk for SPC in individuals diagnosed with meningioma between 20 and 64 years, with an inverse association in the older age group (65+ years). CONCLUSIONS: Meningioma diagnosis is associated with an increased risk for developing secondary cancers. This risk should be discussed with patients treated for meningioma.
BACKGROUND: There are limited data on whether primary diagnosis of meningioma may be associated with development of secondary primary cancer (SPC). METHODS: All meningioma cases (ICD-O-3 morphology codes 9530/0-9539/3) diagnosed in Jewish Israelis ≥ 20 years 1990 through 2015 registered in the Israel National Cancer Registry (INCR) were retrieved. All subsequent cancers occurring more than 6 months after meningioma diagnosis were identified. Risk of secondary cancer (SPC) was compared to cancer risk in the general population through the calculation of standardized incidence ratios (SIRs) and excess absolute risks (EARs). SIRs were stratified by type of second cancer, sex, and age group. Cox regression models were used to estimate hazard ratios of developing SPC. RESULTS: Overall, 8044 meningioma cases were identified: mean age at diagnosis was 64.0 ± 14.1 years. Of these, 927 (11.5%) were diagnosed with SPC (SIR 1.6, 95% CI 1.5-1.7). SPC risk was elevated in men (SIR 1.6, 95% CI 1.5-1.9) and women (SIR 1.6, 95% CI 1.5-1.8) diagnosed with meningioma in univariable analyses. Cancers most commonly encountered in the studied population were breast (17.6%), colorectal (13.4%), lung (8.1%), prostate (5%), and bladder (4.6%) cancer. In multivariable analyses, 10+ year increment in age at meningioma diagnosis was significantly associated with higher risk for SPC in individuals diagnosed with meningioma between 20 and 64 years, with an inverse association in the older age group (65+ years). CONCLUSIONS: Meningioma diagnosis is associated with an increased risk for developing secondary cancers. This risk should be discussed with patients treated for meningioma.
Authors: Judith L Kok; Jop C Teepen; Flora E van Leeuwen; Wim J E Tissing; Sebastian J C M M Neggers; Helena J van der Pal; Jacqueline J Loonen; Dorine Bresters; Birgitta Versluys; Marry M van den Heuvel-Eibrink; Eline van Dulmen-den Broeder; Margriet van der Heiden-van der Loo; Berthe M P Aleman; Laurien A Daniels; Cornelis J A Haasbeek; Bianca Hoeben; Geert O Janssens; John H Maduro; Foppe Oldenburger; Caroline van Rij; Robbert J H A Tersteeg; Michael Hauptmann; Leontien C M Kremer; Cécile M Ronckers Journal: Neuro Oncol Date: 2019-02-19 Impact factor: 12.300
Authors: Francesco Felicetti; Nicoletta Fortunati; Diego Garbossa; Eleonora Biasin; Roberta Rudà; Dino Daniele; Emanuela Arvat; Andrea Corrias; Franca Fagioli; Enrico Brignardello Journal: J Cancer Res Clin Oncol Date: 2015-01-22 Impact factor: 4.553
Authors: Kyle Strodtbeck; Andrew Sloan; Lisa Rogers; Paul Graham Fisher; Duncan Stearns; Laura Campbell; Jill Barnholtz-Sloan Journal: J Neurooncol Date: 2013-02-08 Impact factor: 4.130